Intercept Pharmaceuticals (Part IIa) - Quick Takeaways On OCA From EASL Abstracts And Presentations
- This report provides some brief insights on the implications of the new data on OCA's potential, chances for approval, and other commentary.
- Intercept’s OCA continues to demonstrate statistically significant superiority over placebo on surrogate markers of liver disease that are correlated with clinical outcomes.
- Important implications of NAFLD with Diabetes and Cardiovascular Outcomes is bullish for NASH thesis.
- Early Preclinical Data suggest broader utility of OCA.